217 related articles for article (PubMed ID: 30467701)
1. Economic Burden of Renal Cell Carcinoma-Part I: An Updated Review.
Chien CR; Geynisman DM; Kim B; Xu Y; Shih YT
Pharmacoeconomics; 2019 Mar; 37(3):301-331. PubMed ID: 30467701
[TBL] [Abstract][Full Text] [Related]
2. Economic burden of renal cell carcinoma: Part I--an updated review.
Shih YC; Chien CR; Xu Y; Pan IW; Smith GL; Buchholz TA
Pharmacoeconomics; 2011 Apr; 29(4):315-29. PubMed ID: 21395351
[TBL] [Abstract][Full Text] [Related]
3. Budget impact analysis of first-line treatment with pazopanib for advanced renal cell carcinoma in Spain.
Villa G; Hernández-Pastor LJ
BMC Cancer; 2013 Sep; 13():399. PubMed ID: 24004638
[TBL] [Abstract][Full Text] [Related]
4. Economic evaluation of sunitinib versus pazopanib and best supportive care for the treatment of metastatic renal cell carcinoma in Chile: cost-effectiveness analysis and a mixed treatment comparison.
Vargas C; Balmaceda C; Rodríguez F; Rojas R; Giglio A; Espinoza MA
Expert Rev Pharmacoecon Outcomes Res; 2019 Oct; 19(5):609-617. PubMed ID: 30758237
[No Abstract] [Full Text] [Related]
5. Rising Economic Burden of Renal Cell Carcinoma among Elderly Patients in the USA: Part II-An Updated Analysis of SEER-Medicare Data.
Shih YT; Xu Y; Chien CR; Kim B; Shen Y; Li L; Geynisman DM
Pharmacoeconomics; 2019 Dec; 37(12):1495-1507. PubMed ID: 31286464
[TBL] [Abstract][Full Text] [Related]
6. Cost-utility of Sunitinib Versus Pazopanib in Metastatic Renal Cell Carcinoma in Canada using Real-world Evidence.
Nazha S; Tanguay S; Kapoor A; Jewett M; Kollmannsberger C; Wood L; Bjarnason GAG; Heng D; Soulières D; Reaume MN; Basappa N; Lévesque E; Dragomir A
Clin Drug Investig; 2018 Dec; 38(12):1155-1165. PubMed ID: 30267257
[TBL] [Abstract][Full Text] [Related]
7. Economic Burden of Metastatic Clear-Cell Renal Cell Carcinoma for French Patients Treated With Targeted Therapies.
Cholley T; Thiery-Vuillemin A; Limat S; Hugues M; Calcagno F; Mouillet G; Anota A; Nerich V
Clin Genitourin Cancer; 2019 Feb; 17(1):e227-e234. PubMed ID: 30502046
[TBL] [Abstract][Full Text] [Related]
8. The burden of illness associated with renal cell carcinoma in the United States.
Lang K; Danchenko N; Gondek K; Schwartz B; Thompson D
Urol Oncol; 2007; 25(5):368-75. PubMed ID: 17826652
[TBL] [Abstract][Full Text] [Related]
9. Economic burden of renal cell carcinoma among older adults in the targeted therapy era.
Kale HP; Mays DP; Nadpara PA; Slattum PW; Paul AK; Carroll NV
Urol Oncol; 2019 Jun; 37(6):356.e19-356.e28. PubMed ID: 30846388
[TBL] [Abstract][Full Text] [Related]
10. Clinical and Economic Outcomes in Elderly Advanced Renal Cell Carcinoma Patients Starting Pazopanib or Sunitinib Treatment: A Retrospective Medicare Claims Analysis.
Vogelzang NJ; Pal SK; Ghate SR; Swallow E; Li N; Peeples M; Zichlin ML; Meiselbach MK; Perez JR; Agarwal N
Adv Ther; 2017 Nov; 34(11):2452-2465. PubMed ID: 29076108
[TBL] [Abstract][Full Text] [Related]
11. Can a Joint Assessment Provide Relevant Information for National/Local Relative Effectiveness Assessments? An In-Depth Comparison of Pazopanib Assessments.
Kleijnen S; Fathallah M; van der Linden MW; Vancraeynest P; Dahmani B; Timoney A; De Boer A; Leufkens HG; Goettsch WG
Value Health; 2015 Jul; 18(5):663-72. PubMed ID: 26297095
[TBL] [Abstract][Full Text] [Related]
12. Patterns of practice and pharmacoeconomic analysis of the management of patients with metastatic renal cell carcinoma (mRCC) in Greece--the CRISIS study. A retrospective analysis by the Hellenic Genitourinary Cancer Group (HGUCG).
Tsironis G; Koutsoukos K; Athanasakis K; Tsiara A; Tzannis K; Gerolympou M; Visvikis A; Oikonomopoulos G; Kollia A; Giannopoulou E; Dimitra M; Kostouros E; Papatsoris A; Dellis A; Stravodimos K; Varkarakis I; Samantas E; Aravantinos G; Kentepozidis N; Christodoulou C; Bozionelou V; Dimopoulos MA; Bamias A
Expert Rev Pharmacoecon Outcomes Res; 2019 Aug; 19(4):491-501. PubMed ID: 30417707
[No Abstract] [Full Text] [Related]
13. Current and predicted cost of metastatic renal cell carcinoma in Finland.
Purmonen T; Nuttunen P; Vuorinen R; Pyrhönen S; Kataja V; Kellokumpu-Lehtinen P
Acta Oncol; 2010 Aug; 49(6):837-43. PubMed ID: 20331406
[TBL] [Abstract][Full Text] [Related]
14. Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation.
Thompson Coon J; Hoyle M; Green C; Liu Z; Welch K; Moxham T; Stein K
Health Technol Assess; 2010 Jan; 14(2):1-184, iii-iv. PubMed ID: 20028613
[TBL] [Abstract][Full Text] [Related]
15. Pazopanib: an orally administered multi-targeted tyrosine kinase inhibitor for locally advanced or metastatic renal cell carcinoma.
Koc G; Wang X; Luo Y
Can J Urol; 2011 Dec; 18(6):5991-7. PubMed ID: 22166325
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of pazopanib versus sunitinib for metastatic renal cell carcinoma in the United Kingdom.
Amdahl J; Diaz J; Sharma A; Park J; Chandiwana D; Delea TE
PLoS One; 2017; 12(6):e0175920. PubMed ID: 28636648
[TBL] [Abstract][Full Text] [Related]
17. Pazopanib has equivalent anti-tumor effectiveness and lower Total costs than Sunitinib for treating metastatic or advanced renal cell carcinoma: a meta-analysis.
Deng H; Huang Y; Hong Z; Yuan X; Cao Z; Wei Y; Zhang W
BMC Cancer; 2019 May; 19(1):489. PubMed ID: 31122210
[TBL] [Abstract][Full Text] [Related]
18. Economic burden of renal cell carcinoma in the US: Part II--an updated analysis.
Shih YC; Chien CR; Xu Y; Pan IW; Smith GL; Buchholz TA
Pharmacoeconomics; 2011 Apr; 29(4):331-41. PubMed ID: 21395352
[TBL] [Abstract][Full Text] [Related]
19. Cost-Effectiveness of Pazopanib Versus Sunitinib for Renal Cancer in the United States.
Benedict A; Ramaswamy K; Sandin R
J Manag Care Spec Pharm; 2015 Sep; 21(9):834-40. PubMed ID: 26308230
[TBL] [Abstract][Full Text] [Related]
20. Pazopanib for the treatment of metastatic renal cell carcinoma.
Pick AM; Nystrom KK
Clin Ther; 2012 Mar; 34(3):511-20. PubMed ID: 22341567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
